OncoMatch/Clinical Trials/NCT04199741
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Is NCT04199741 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including 89Zr-DFO-SC16.56 and SC16.56, Phase I, Cohort 2 for small cell lung cancer.
Treatment: 89Zr-DFO-SC16.56 · SC16.56, Phase I, Cohort 2 · SC16.56, Phase I, Cohort 3 · SC16.56, Phase II — The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: DLL3 any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04199741 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require DLL3?
Yes, DLL3 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages